Subject(s)
Hyperoxaluria/surgery , Kidney Transplantation , Liver Transplantation , Living Donors , Adult , Child , Female , Humans , Hyperoxaluria/classification , Infant , Male , Nuclear Family , Transaminases/deficiency , Treatment OutcomeABSTRACT
BACKGROUND: Tacrolimus is usually administered orally based on mg/kg or the trough concentration (Cmin) in whole blood. However, it is not easy to determine the optimal oral dose because of considerable variation of tacrolimus bioavailability between patients. In this study, pharmacokinetics of tacrolimus in various conditioning kidney transplant recipients was investigated. METHODS: 1) Thirty-three patients were randomly assigned to participate in two groups. In 17 patients, tacrolimus was administered orally after an overnight fast with breakfast given 1 h later, and in the other 16 patients it was administered orally 1 h after breakfast. 2) In 4 patients, the same dose tacrolimus was given after an overnight fast and 0.5 h after breakfast on two consecutive days. 3) Five patients who underwent continuous ambulatory peritoneal dialysis (CAPD) before transplantation were studied. All patients were investigated in daily profile of tacrolimus blood levels. RESULTS: There was a strong correlation between area under the curve (AUC) and the trough concentration in both preprandial and postprandial oral administration, with correlation coefficients of 0.838 and 0.860, respectively. Significant increases in the peak concentration (Cmax) and AUC were observed in the preprandial oral administration subjects. Absorption of CAPD patients was obviously insufficient. CONCLUSIONS: Since tacrolimus absorption was better under fasted condition than under the presence of food, it is thought that the highest medicine effect with the least dosage is provided by preprandial oral administration. Furthermore, preprandial oral administration is recommended from a respect of economic burden reduction and side effect reduction.
Subject(s)
Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation/immunology , Tacrolimus/pharmacokinetics , Administration, Oral , Adult , Aged , Area Under Curve , Biological Availability , Female , Graft Rejection/metabolism , Graft Rejection/prevention & control , Humans , Immunoenzyme Techniques , Immunosuppressive Agents/administration & dosage , Male , Middle Aged , Peritoneal Dialysis, Continuous Ambulatory , Statistics, Nonparametric , Tacrolimus/administration & dosage , Transplantation ConditioningSubject(s)
Arteriovenous Fistula/therapy , Embolization, Therapeutic , Kidney Transplantation/pathology , Postoperative Complications/pathology , Adolescent , Adult , Arteriovenous Fistula/pathology , Biopsy , Biopsy, Needle , Child , Child, Preschool , Female , Humans , Kidney Transplantation/physiology , Male , Middle Aged , Postoperative Complications/therapy , Retrospective StudiesABSTRACT
The purpose of this study was to determine the perioperative factors that influence patient and graft outcome in living-related liver transplantation (LRLT). Between April 1995 and October 1998, we performed a series of 46 LRLT procedures, including 11 adult cased, at our institute. Mean age and weight of the recipients were 12.0 +/- 2.3 years and 23.7 +/- 2.6 kg, respectively. Seven out of the 46 patients had renal failure and received hemodialysis therapy before and after LRLT or kidney transplantation. The recipients were divided into two groups: those who survived for 7-48 months after LRLT (group 1, n = 36), and those who died within 4 months after surgery (group 2, n = 10). Factors analyzed included recipient age and weight, graft/recipient body weight ratio (G/R ratio), emergent vs elective surgery, United Network for Organ Sharing (UNOS) status, presence of preoperative plasmapheresis (PEX) and renal failure, and so on. Recipients in group 1 compared with group 2 had less advanced liver disease (i. e., a lower rate of emergent surgery, 14% vs 50%, and fewer patients with UNOS status 1, 14% versus 70%; P < 0.05 and P < 0.001, respectively). Group 1 recipients also had a lower percentage of preoperative treatment with plasmapheresis (22% vs 70%, P < 0.01). However, neither the G/R ratio nor the presence of renal failure affected the patient survival rate. In conclusion, factors independently associated with reduced patient survival after LRLT include emergent surgery, Child-Pugh class, UNOS status 1, and preoperative plasmapheresis.
Subject(s)
Liver Transplantation/statistics & numerical data , Living Donors , Adolescent , Adult , Body Weight , Child , Child, Preschool , Family , Female , Follow-Up Studies , Humans , Infant , Kidney Transplantation/mortality , Kidney Transplantation/physiology , Kidney Transplantation/statistics & numerical data , Liver Transplantation/mortality , Liver Transplantation/physiology , Male , Middle Aged , Plasmapheresis , Retrospective Studies , Survival Rate , Time FactorsABSTRACT
BACKGROUND: We have previously demonstrated that induction of mixed lymphohematopoietic chimerism resulted in donor specific renal allograft tolerance without the need for chronic immunosuppression in nonhuman primates. Here we have tested whether tolerance can be similarly induced for baboon to cynomolgus renal xenografts. METHODS: After preconditioning with anti-thymocyte globulin (ATG), nonlethal total body irradiation, and thymic irradiation, cynomolgus monkeys underwent splenectomy, native nephrectomies, and baboon marrow and renal transplants. Postoperative cyclosporine was given for 28 days. RESULTS: In Group 1 (n=2, survival= 13, 14 days), both animals developed anti-donor immunoglobulin G, had biopsy findings consistent with humoral rejection, and showed rapidly progressive xenograft failure. In Group 2 (n=5, survival=1, 16, 33, 112, 190 days), 15-deoxyspergualine was added to the regimen (Day 0-13). In one long-term survivor, donor specific hyporesponsiveness was first observed (mixed lymphocyte culture [(MLR]) on Day 48. MLR reactivity returned on Day 64 together with the development of anti-donor antibody and subsequent xenograft failure on Day 112. Donor specific T-cell hyporesponsiveness was detected in the other long-term survivor for the first 133 days, after which a donor-specific skin xenograft was placed, (survival 24 days). Following the skin graft rejection, a rise in the MLR, development of anti-donor antibody and progressive rejection of the renal xenograft were observed. CONCLUSIONS: Antibody-mediated rejection seems to constitute the major difference between concordant xenografts and allografts. Addition of 15-deoxyspergualine for 2 weeks posttransplant extended concordant primate xenograft survival to 6 months without chronic immunosuppression. In contrast to the allogeneic model, renal transplant acceptance in this xenogeneic system was interrupted by placement of a donor-specific skin graft.
Subject(s)
Bone Marrow Transplantation/immunology , Immune Tolerance/physiology , Kidney Transplantation/immunology , Transplantation, Heterologous/immunology , Animals , Antibodies, Heterophile/analysis , Antibodies, Monoclonal/pharmacology , Female , Graft Rejection/immunology , Graft Survival/drug effects , Guanidines/pharmacology , Immunosuppressive Agents/pharmacology , Macaca fascicularis , Male , Mice , Papio , Skin Transplantation/immunology , T-Lymphocytes/physiology , Time FactorsABSTRACT
BACKGROUND: Multilineage chimerism and long-term acceptance of renal allografts has been produced in non-human primates conditioned with a nonmyeloablative regimen. Our study was undertaken to evaluate the immunological and pathological status of long-term survivors and to define the role of splenectomy and of the primarily vascularized kidney in the regimen. METHOD: Monkeys were treated with the basic regimen, including: total body irradiation, thymic irradiation, antithymocyte globulin, donor bone marrow transplantation, and a 4-week course of cyclosporine after which no further immunosuppression was given. They were divided into four groups according to the timing of kidney transplantation (KTx) and splenectomy as follows; group A (n=13): KTx and splenectomy on the day of donor bone marrow transplantation (day 0); group B (n=3): KTx on day 0 without splenectomy; group C (n=7): splenectomy on day 0 but delayed KTx until 3 to 16 weeks post-donor bone marrow transplantation; group D (n=3): both splenectomy and KTx delayed until day 120 post-donor bone marrow transplantation. RESULTS: In group A, 11 of 13 monkeys developed chimerism and 9 monkeys achieved long-term survival of 4 to 70 months without evidence of chronic vascular rejection. Alloantibodies were detected in only one long-term survivor. In contrast, all three monkeys in group B developed alloantibodies and rejected their allografts. In group C, long-term survival without alloantibody production was observed in two of three monkeys that had developed chimerism. In group D, all three recipients were sensitized and rejected the kidney allografts rapidly after transplantation. CONCLUSIONS: 1) Production of anti-donor antibody was prevented in most recipients that developed mixed chimerism in the regimens with splenectomy at the time of donor bone marrow transplantation. 2) If splenectomy is not included in the initial conditioning regimen, induction of B cell tolerance is less likely and the result is late onset of alloantibody production and allograft rejection. 3) Immediate transplantation of the kidney at the time of recipient conditioning is not essential for induction of donor specific hyporesponsiveness by bone marrow transplantation.
Subject(s)
Immune Tolerance , Immunologic Techniques , Isoantibodies/analysis , Kidney Transplantation/immunology , Animals , Antilymphocyte Serum/pharmacology , Blood Vessels/pathology , Bone Marrow Transplantation , Chimera , Cyclosporine/pharmacology , Graft Rejection , Immunosuppressive Agents/pharmacology , Macaca fascicularis , Male , Renal Circulation , Splenectomy , Survival Analysis , Thymus Gland/radiation effects , Time FactorsSubject(s)
Immunosuppressive Agents/administration & dosage , Kidney Transplantation/immunology , Tacrolimus/administration & dosage , Administration, Oral , Adolescent , Adult , Azathioprine/therapeutic use , Creatinine/blood , Drug Therapy, Combination , Graft Rejection/epidemiology , Humans , Immunosuppressive Agents/blood , Immunosuppressive Agents/therapeutic use , Infusions, Intravenous , Kidney Transplantation/pathology , Methylprednisolone/therapeutic use , Middle Aged , Prospective Studies , Ribonucleosides/therapeutic use , Tacrolimus/blood , Tacrolimus/therapeutic use , Treatment OutcomeSubject(s)
B-Lymphocytes/immunology , Graft Rejection/immunology , Isoantibodies/blood , Kidney Transplantation/immunology , Antibody Formation , Chronic Disease , Creatinine/blood , Flow Cytometry , Histocompatibility Testing , Humans , Kidney Transplantation/physiology , Regression Analysis , Retrospective Studies , T-Lymphocytes/immunologySubject(s)
Kidney Transplantation/methods , Pancreas Transplantation/methods , Adult , Cadaver , Diabetes Mellitus/surgery , Female , Graft Rejection , Humans , Intraoperative Care , Kidney Failure, Chronic/surgery , Kidney Transplantation/mortality , Male , Pancreas Transplantation/mortality , Postoperative Care , Survival RateSubject(s)
Hepatectomy , Liver Transplantation , Liver/physiology , Living Donors , Adolescent , Adult , Analysis of Variance , Blood Loss, Surgical , Blood Transfusion, Autologous , Child , Child, Preschool , Hepatectomy/adverse effects , Hepatectomy/methods , Humans , Infant , Liver Function Tests , Middle Aged , Postoperative Care , Risk FactorsABSTRACT
BACKGROUND: We demonstrated previously that a nonmyeloablative preparative regimen can induce mixed chimerism and allograft tolerance in cynomolgus monkeys. METHODS: The current studies were designed to clarify the importance and toxicity of various elements of the allotolerance conditioning regimen by: fractionating or reducing the whole-body irradiation (WBI) dosage; adding deoxyspergualine; or deleting donor bone marrow, cyclosporine, irradiation, or splenectomy. RESULTS: Monkeys treated without donor bone marrow, cyclosporine, or irradiation did not develop chimerism or long-term allograft survival. One of three monkeys treated without splenectomy developed chimerism but died of a surgical complication. The other two did not develop chimerism and rejected by day 117. Six of six monkeys treated with 300 cGy of fractionated WBI developed chimerism. Five of these recipients had long-term graft survival. Only two of four monkeys treated with 250 cGy developed chimerism, so a 2-week course of deoxyspergualine was added. This led to chimerism in two monkeys, but one died of ureteral stenosis and the other died of allograft rejection. An unanticipated high incidence of ureteral complications felt to be secondary to rejection episodes and ischemic injury was observed in the long-term surviving animals. CONCLUSIONS: All parameters of the original preparative regimen seem to be essential for consistent success. The degree of lymphocyte depletion was proportional to the WBI dose. Long-term graft survival was observed only in recipients achieving lymphocyte chimerism of > 1.5%. In this model, lymphocyte depletion seems to be the best predictor of chimerism, and significant lymphocyte chimerism seems to be important in achieving tolerance.
Subject(s)
Macaca fascicularis/immunology , Transplantation Chimera/physiology , Transplantation Conditioning/methods , Animals , Cyclosporine/therapeutic use , Flow Cytometry , Graft Rejection/prevention & control , Graft Survival/drug effects , Guanidines/therapeutic use , Immune Tolerance , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Leukocyte Count/radiation effects , Lymphocyte Depletion , Male , Pancytopenia/etiology , Transplantation Chimera/immunology , Transplantation, Homologous , Whole-Body Irradiation/adverse effectsSubject(s)
Bone Marrow Transplantation , Graft Survival , Immunosuppression Therapy/methods , Kidney Transplantation/immunology , Transplantation Chimera , Animals , Cyclosporine/therapeutic use , Graft Rejection/prevention & control , Macaca fascicularis , Male , Splenectomy , Thymus Gland/radiation effects , Whole-Body IrradiationABSTRACT
Antibody-mediated rejection appears to constitute the major difference between concordant xenografts and allografts in nonhuman primates. Consistent with its known effect on antibody responses, 5-7 addition of DSG to the conditioning regimen has extended concordant primate xenograft survival for up to 6 months after discontinuation of conventional immunosuppression. In contrast to our observations in recipients of renal allografts, donor-specific skin graft rejection can occur and even in long-term recipients may induce rejection of a previously accepted renal xenograft.
Subject(s)
Bone Marrow Transplantation/immunology , Graft Rejection/immunology , Kidney Transplantation/immunology , Transplantation, Heterologous/immunology , Animals , Antibodies, Heterophile/blood , Antibody Formation , Antilymphocyte Serum/therapeutic use , Cyclosporine/pharmacology , Graft Survival , Guanidines/pharmacology , Immunity, Cellular , Immunoglobulin G/blood , Immunosuppression Therapy/methods , Immunosuppressive Agents/pharmacology , Macaca fascicularis , Papio , Splenectomy , Thymus Gland/radiation effects , Transplantation, Heterologous/pathology , Whole-Body IrradiationSubject(s)
Bone Marrow Transplantation/physiology , Graft Survival , Kidney Transplantation/physiology , Transplantation, Heterologous/physiology , Animals , Bone Marrow Transplantation/immunology , Bone Marrow Transplantation/pathology , Chimera , Creatinine/blood , Graft Rejection/pathology , Guanidines/therapeutic use , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Kidney Transplantation/pathology , Macaca fascicularis , Papio , Transplantation, Heterologous/immunology , Transplantation, Heterologous/pathologySubject(s)
Diabetes Mellitus, Type 1/surgery , Diabetic Nephropathies/surgery , Graft Rejection/drug therapy , Graft Survival/physiology , Kidney Transplantation/immunology , Pancreas Transplantation/immunology , Tacrolimus/therapeutic use , Adult , Amylases/urine , Biomarkers/urine , Blood Glucose/metabolism , Cadaver , Creatinine/blood , Cyclosporine/blood , Cyclosporine/therapeutic use , Female , Follow-Up Studies , Glucose Tolerance Test , Glycated Hemoglobin/analysis , Graft Rejection/diagnosis , Humans , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/physiology , Male , Pancreas Transplantation/physiology , Recurrence , Tacrolimus/blood , Time Factors , Tissue Donors , Urine/cytologyABSTRACT
Vascular access devices that are completely implanted have been used for treatment of cancer patients. Vascular access devices are useful for transarterial infusion of anticancer drugs, intravenous hyperalimentation, and drainage of bile juice in obstructive jaundice. These systems have several advantages in the care of patients: they are sealed, they have no external tubes, and they may be useful for blood or biliary sample and intravenous hyperalimentation or chemotherapy. There are only minimal discomforts related to the implantation procedure and no need for routine external catheter care. Most importantly, the quality of the patient's life is dramatically improved without external tubes. For these reasons, we believe that vascular access devices should be indicated for patients with malignant tumors as much as placement of these devices is technically feasible.
Subject(s)
Catheters, Indwelling , Neoplasms/therapy , Bile , Catheterization, Central Venous/instrumentation , Drainage/instrumentation , Humans , Infusions, Intra-Arterial/instrumentationABSTRACT
A double filtration plasmapheresis (DFPP) technique and ex vivo immunoadsorption were applied to remove natural antibodies and avoid hyperacute rejection in discordant xenotransplantation. A swine heart was heterotopically transplanted into a dog's neck after DFPP and ex vivo immunoadsorption using a swine spleen or liver. Mean graft survival time was prolonged to 240 +/- 141 min in the group treated by combined DFPP and splenic adsorption, and 225 +/- 62 min in the group treated by combined DFPP and hepatic adsorption, whereas it was 9 +/- 5 min in the group without any treatment (p < 0.01). Mean removal rates of IgG and IgM were 85.5% and 93.3%, respectively. Anti-swine lymphocytotoxic antibodies and hemagglutination antibodies were also effectively removed. Deposits of canine IgM and C3 on the vascular endothelium of the graft were observed on immunofluorescence, which suggested that natural antibodies in the IgM fraction played an important role in xenohyperacute rejection.